(Internet) 06/22/06 A patient's urologist may be the key to whether a prostate cancer patient receives hormonal therapy rather than the stage, and type of cancer he has, a new study shows. Led by Dr. Vahakn Shahinian, from the University of Texas Medical Branch in Galveston the researchers looked at the pattern of hormone deprivation therapy within 6 months of diagnosis to determine the part attributed to the urologist versus patient and tumor characteristics. The study appears in the June 21 issue of the Journal of the National Cancer Institute. "The substantial variance in use of androgen deprivation therapy attributable to the urologist, independent of patient factors, suggest that interventions at the level of the urologist may be an effective way to modify the use of this therapy for prostate cancer," the researchers wrote.